India vs Landlocked developing countries (LLDCs): Percentage of bloodstream infection due to Escherichia coli resistant
India
77.5%
in 2022
Landlocked developing countries (LLDCs)
74.2%
in 2022
India rank
4th
Landlocked developing countries (LLDCs) rank
3rd
Percentage of bloodstream infection due to Escherichia coli resistant over time
- India
- Landlocked developing countries (LLDCs)
How they compare
India currently reports 77.5% against 74.2% in Landlocked developing countries (LLDCs), a difference of 3.3%.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was India ahead.
India ranks 4th and Landlocked developing countries (LLDCs) ranks 3rd of 50 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Landlocked developing countries (LLDCs) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 78.2% | 32.3% | 45.9% | India |
| 2020s | 80.6% | 73.7% | 7.0% | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, India or Landlocked developing countries (LLDCs)?
- India, at 77.5% against 74.2% in Landlocked developing countries (LLDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between India and Landlocked developing countries (LLDCs)?
- 3.3%, with India ahead.
- How many years of comparable data are there for India and Landlocked developing countries (LLDCs)?
- 6 years are reported by both, from 2017 to 2022.
- How do India and Landlocked developing countries (LLDCs) rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- India ranks 4th and Landlocked developing countries (LLDCs) ranks 3rd of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.